Luye Pharma Receives U.S. FDA Clearance to Initiate Clinical Trials for Its Novel Antidepressant LY03021
Shanghai, November 17, 2026 — Luye Pharma Group today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LY03021, a next-generation central nervous system (CNS) drug candidate developed by the company and intended ...
November 17,2026
Luye Pharma Announces Renewed Inclusion of Its Innovative Antidepressant Ruoxinlin® in China’s 2026 National Reimbursement Drug List
Shanghai, November 15, 2026 — Luye Pharma Group today announced that it has successfully renewed the coverage of Ruoxinlin® (toludesvenlafaxine hydrochloride sustained-release tablets), a Class 1 innovative drug in China for the treatment of major depressive disorder (MDD), by ...
November 15,2026